Evidence map›Paper›PMID 39797728›Full record

ArticleNucleic acids research2025

inDrops-2: a flexible, versatile and cost-efficient droplet microfluidic approach for high-throughput scRNA-seq of fresh and preserved clinical samples.

Simonas Juzenas, Karolis Goda, Vaidotas Kiseliovas, Justina Zvirblyte, Alvaro Quintinal-Villalonga, Juozas Siurkus, Juozas Nainys, Linas Mazutis

Erratum issuedAbstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Simonas JuzenasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, 10257, Lithuania.ORCID 0000-0001-9293-0691
Karolis GodaInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, 10257, Lithuania.
Vaidotas KiseliovasComputational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, NY, 10065, USA.
Justina ZvirblyteInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, 10257, Lithuania.
Alvaro Quintinal-VillalongaDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, NY, 10065 USA.
Juozas SiurkusThermo Fisher Scientific Baltics, Research and Development, Vilnius, 02241, Lithuania.
Juozas NainysDroplet Genomics, Vilnius, 08114, Lithuania.
Linas MazutisInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, 10257, Lithuania.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Alan and Sandra Gerry MetastasisEuropean Regional Development Fund 01.2.2-LMT-K-718-04-0002HORIZON EUROPE Marie Skłodowska-Curie Actions 101030265NCI NIH HHS P30 CA008748Research Council of LithuaniaTumour Ecosystems Center
6 · The paper itself

Abstract

The expansion of single-cell analytical techniques has empowered the exploration of diverse biological questions at the individual cells. Droplet-based single-cell RNA sequencing (scRNA-seq) methods have been particularly widely used due to their high-throughput capabilities and small reaction volumes. While commercial systems have contributed to the widespread adoption of droplet-based scRNA-seq, their relatively high cost limits the ability to profile large numbers of cells and samples. Moreover, as the scale of single-cell sequencing continues to expand, accommodating diverse workflows and cost-effective multi-biospecimen profiling becomes more critical. Herein, we present inDrops-2, an open-source scRNA-seq technology designed to profile live or preserved cells with a sensitivity matching that of state-of-the-art commercial systems but at a 6-fold lower cost. We demonstrate the flexibility of inDrops-2, by implementing two prominent scRNA-seq protocols, based on exponential and linear amplification of barcoded-complementary DNA, and provide useful insights into the advantages and disadvantages inherent to each approach. We applied inDrops-2 to simultaneously profile multiple human lung carcinoma samples that had been subjected to cell preservation, long-term storage and multiplexing to obtain a multiregional cellular profile of the tumor microenvironment. The scalability, sensitivity and cost efficiency make inDrops-2 stand out among other droplet-based scRNA-seq methods, ideal for large-scale studies on rare cell molecular signatures.

Indexed as

High-Throughput Nucleotide SequencingMicrofluidic Analytical TechniquesMicrofluidicsRNA-SeqSequence Analysis, RNASingle-Cell AnalysisCell Line, TumorCost-Benefit AnalysisHumansLung NeoplasmsSingle-Cell Gene Expression Analysis

Identifiers

PMID39797728
PMCPMC11724362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.